DNA Sequencing Startups Aim to Reduce Cost, Increase Meaning in the Data
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward...Read More
Biotech, Humanized.
About Stacy Lawrence
Stacy Lawrence has been writing and editing about the business of emerging technologies for almost 20 years. Most recently, she was editor-in-chief of FierceBiotech, where she covered biotech and medtech. She’s also held spots as the biopharma business bureau editor with Elsevier and the finance columnist with biotechnology industry publication BioCentury. Stacy has contributed to publications including Nature Biotechnology, San Francisco Business Times, New Scientist, MIT Technology Review, Business 2.0, and Wired.
Latest Contributions
Complexity in Motion: Multi-Omics Tools Unravel Path From Genotype to Phenotype
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward...Read More
Biopharma Gets Serious, In a Hurry, About Virtual Clinical Trials
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward...Read More
Beyond CAR-T: New Engineered Immune Cell Types Head to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward...Read More
Cancer Drugmakers Seek to Broaden Use of Tissue-Agnostic Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward...Read More
Solid Tumors Have Eluded CAR-T, But Novel Targets and Techniques Are At Hand
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward...Read More
Automation and Miniaturization Are Upon Us: Gritstone’s Mission to Make Personalized Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward...Read More
HBV Curative Treatments Gear Up in the Clinic, as HCV Combos Help to Guide the Way
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward...Read More